Abbott Laboratories (ABL) Stock Statistics & Valuation Metrics
Total Valuation
Abbott Laboratories has a market cap or net worth of EUR 163.99B. The enterprise value is EUR 185.82B.
- Market Cap
- EUR 163.99B
- Enterprise Value
- EUR 185.82B
Share Statistics
Abbott Laboratories has 1,730,383,300 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 1,730,383,300
- Owned by Insiders
- 0.48%
- Owned by Institutions
- 3.63%
Financial Efficiency
Abbott Laboratories’s return on equity (ROE) is 0.13 and return on invested capital (ROIC) is 8.43%.
- Return on Equity (ROE)
- 0.13
- Return on Assets (ROA)
- 0.08
- Return on Invested Capital (ROIC)
- 8.43%
- Return on Capital Employed (ROCE)
- 0.11
- Revenue Per Employee
- 385.46K
- Profits Per Employee
- 56.73K
- Employee Count
- 115,000
- Asset Turnover
- 0.51
- Inventory Turnover
- 3.04
Valuation Ratios
The current PE Ratio of Abbott Laboratories is 39.33. Abbott Laboratories’s PEG ratio is -0.59.
- PE Ratio
- 39.33
- PS Ratio
- 3.81
- PB Ratio
- 3.61
- Price to FCF
- 21.07
- Price to Operating Cash Flow
- 18.64
- PEG Ratio
- -0.59
Income Statement
In the last 12 months, Abbott Laboratories had revenue of 44.33B and earned 6.52B in profits. Earnings per share was 3.74.
- Revenue
- 44.33B
- Gross Profit
- 24.61B
- Operating Income
- 8.05B
- Pretax Income
- 8.47B
- Net Income
- 6.52B
- EBITDA
- 11.92B
- Earnings Per Share (EPS)
- 3.74
Cash Flow
In the last 12 months, operating cash flow was 9.90B and capital expenditures -1.19B, giving a free cash flow of 8.72B billion.
- Operating Cash Flow
- 9.90B
- Free Cash Flow
- 8.72B
- Free Cash Flow per Share
- 5.02
Dividends & Yields
Abbott Laboratories pays an annual dividend of EUR 0.55, resulting in a dividend yield of 2.29%
- Dividend Per Share
- EUR 0.55
- Dividend Yield
- 2.29%
- Payout Ratio
- 46.00%
- Free Cash Flow Yield
- 4.75%
- Earnings Yield
- 2.55%
Stock Price Statistics
- Beta
- 0.30
- 52-Week Price Change
- -12.04%
- 50-Day Moving Average
- 91.07
- 200-Day Moving Average
- 86.52
- Relative Strength Index (RSI)
- 62.12
- Average Volume (3m)
- 719
Important Dates
Abbott Laboratories upcoming earnings date is Jan 27, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Oct 21, 2026
- Next Earnings Date
- Jan 27, 2027
- Ex-Dividend Date
- Jul 15, 2026
Financial Position
Abbott Laboratories as a current ratio of 1.58, with Debt / Equity ratio of 28.90%
- Current Ratio
- 1.58
- Quick Ratio
- 1.18
- Debt to Market Cap
- 0.06
- Net Debt to EBITDA
- 0.55
- Interest Coverage Ratio
- 23.60
Taxes
In the past 12 months, Abbott Laboratories has paid 1.94B in taxes.
- Income Tax
- 1.94B
- Effective Tax Rate
- 0.23
Enterprise Valuation
Abbott Laboratories EV to EBITDA ratio is 21.76, with an EV/FCF ratio of 24.23.
- EV to Sales
- 4.38
- EV to EBITDA
- 21.76
- EV to Free Cash Flow
- 24.23
- EV to Operating Cash Flow
- 21.33
Balance Sheet
Abbott Laboratories has EUR 5.60B in cash and marketable securities with EUR 32.61B in debt, giving a net cash position of -EUR 27.00B billion.
- Cash & Marketable Securities
- EUR 5.60B
- Total Debt
- EUR 32.61B
- Net Cash
- -EUR 27.00B
- Net Cash Per Share
- -EUR 15.61
- Tangible Book Value Per Share
- -EUR 0.40
Margins
Gross margin is 57.12%, with operating margin of 15.24%, and net profit margin of 9.75%.
- Gross Margin
- 57.12%
- Operating Margin
- 15.24%
- Pretax Margin
- 13.61%
- Net Profit Margin
- 9.75%
- EBITDA Margin
- 20.13%
- EBIT Margin
- 14.88%
Analyst Forecast
The average price target for Abbott Laboratories is EUR 108.82, which is 11.43% higher than the current price. The consensus rating is Strong Buy
- Price Target
- EUR 108.82
- Price Target Upside
- 14.26% Upside
- Analyst Consensus
- Strong Buy
- Analyst Count
- 19
- Revenue Growth Forecast
- 4.64%
- EPS Growth Forecast
- ―
Scores
- Smart Score
- 6
- AI Score
- ―